Comparison of the efficacy of moclobemide and fluvoxamine in elderly patients with a severe depressive episode

1993 ◽  
Vol 8 (6) ◽  
pp. 319-324 ◽  
Author(s):  
JP Bocksberger ◽  
JP Gachoud ◽  
J Richard ◽  
Ρ Dick
Keyword(s):  
Side Effects ◽  
Elderly Patients ◽  
Psychomotor Retardation ◽  
Antidepressant Effect ◽  
Reversible Inhibitor ◽  
Double Blind Study ◽  
Double Blind ◽  
New Class ◽  
Low Incidence ◽  
To Receive

SummaryIn a double-blind study carried out on elderly patients (older than 65 years) the efficacy and tolerability of the new antidepressant moclobemide was compared. Moclobemide belongs to a new class of substances called RIMA (Reversible inhibitor of the monoamine oxidase type A). Fluvoxamine, a selective reuptake-inhibitor of 5-HT, belongs to a class of antidepressants known for their better tolerability compared to tricyclic especially with elderly patients. Forty elderly patients (mean age 75 years) with major depression (according to DSM III) were randomized to receive either moclobemide (300 mg) or fluvoxamine (100 mg) twice daily. Dosages were increased when necessary on day 8, to a maximum of 450 mg moclobemide or 200 mg fluvoxamine and in most cases were maintained at these levels for the remainder of the study period (four weeks). Moclobemide was more effective than fluvoxamine showing a marked antidepressant effect and an earlier effect on psychomotor retardation. The two drugs were well tolerated showing a low incidence of side effects.

A Double-Blind Out-Patient Trial of Indalpine vs Mianserin

1985 ◽  
Vol 147 (3) ◽  
pp. 306-309 ◽  
Author(s):  
G. J. Naylor ◽  
B. Martin
Keyword(s):  
Side Effects ◽  
Treated Group ◽  
Blind Study ◽  
Antidepressant Effect ◽  
Double Blind Study ◽  
Double Blind ◽  
Significant Difference

SummaryIndalpine 150 mg per day and mianserin 60 mg per day were compared in a double-blind study of 65 depressed out-patients: 52 patients completed the 4-week trial. At the end of four weeks there was no significant difference in antidepressant effect between the two drugs; but in the first two weeks, improvement in the mianserin-treated group was significantly greater than that in the indalpine group. The mianserin-treated group reported more side-effects of sedation (eg. drowsiness, clumsiness, heaviness of limbs etc.) and one patient on indalpine developed a mild leucopenia.

Ergot derivatives in the prophylaxis of migraine: a multicentric study with a timed-release dihydroergotamine formulation

Cephalalgia ◽  
1983 ◽  
Vol 3 (1_suppl) ◽  
pp. 151-155 ◽  
Author(s):  
N. Martucci ◽  
V. Manna ◽  
P. Mattesi ◽  
G. Troiani ◽  
G. C. Manzoni ◽  
...  
Keyword(s):  
Side Effects ◽  
Sono State ◽  
Double Blind Study ◽  
Prophylactic Effect ◽  
Therapeutic Activity ◽  
Weight Changes ◽  
Double Blind ◽  
Multicentric Study ◽  
Recurrent Headache ◽  
Low Incidence

In this multicentric random double-blind study versus placebo, the therapeutic activity of timed-release dihydroergotamine preparation 10 mg/per os/day has been tested in 90 patients affected by common migraine. The drug presented a prophylactic effect on recurrent headache, mainly on night and awakening migraine. A low incidence of side-effects with no weight changes or other effects on physiologic events was registered. Les résultas obtenus dans cette étude contrôlée, en double aveugle, sur une serie de 90 malades porteurs de ‘migraine commune’, montre que la dihydroergotamine retard est active. Cette substance sembre réellment prévenir les crises du réveil et de la nuit. La tolérance clinique a été exellente. In questo studio multicentrico in doppio cieco randomizzato versus placebo è stata valutata l'attività terapeutica di una diidroergotamina a liberazione programmata (10 mg/per os/die) in 90 pazienti affetti da emicranie comune. Il farmaco ha dimostrato di possedere un effetto sulle cefalee ricorrenti e soprattutto sulla emicrania notturna e del risveglio. Sono state registrate una bassa incidenza di effetti collaterali e nessuna variazione del peso corporeo e di altri parametri fisiologici.

scholarly journals The Influence of Adrenaline on Postoperative Analgesia after Subarachnoid Morphine

1993 ◽  
Vol 21 (1) ◽  
pp. 79-84 ◽  
Author(s):  
M. J. Paech
Keyword(s):  
Side Effects ◽  
Postoperative Analgesia ◽  
Saline Group ◽  
Control Group ◽  
Double Blind Study ◽  
Gynaecological Surgery ◽  
Normal Saline Group ◽  
Double Blind ◽  
Significant Difference ◽  
To Receive

A randomised, double-blind study was conducted to investigate the postoperative effects of subarachnoid morphine, with or without adrenaline, after major gynaecological surgery. Seventy-five women having spinal anaesthesia combined with either sedation or general anaesthesia were randomised to receive subarachnoid morphine 0.25 mg with (group MA) or without (group M) adrenaline 200 ūg; or normal saline (group C). Groups M (n=22) and MA (n=25) differed significantly from control (n=23) with respect to the quality and duration of postoperative analgesia (P<0.0002) and to a higher incidence of pruritus (P<0.02). Groups were similar with respect to the incidence of other postoperative side-effects and respiratory data, although the latter showed a trend to less hypoxaemia in the control group. There was no significant difference in any outcome between groups MA and M. It was concluded that, under the study conditions in a post-gynaecological surgery population, the addition of adrenaline to subarachnoid morphine was of no benefit.

scholarly journals Efficacy of Addition of Fentanyl to Epidural Bupivacaine on Postoperative Analgesia after Thoracotomy for Lung Resection in Infants

2008 ◽  
Vol 109 (5) ◽  
pp. 890-894 ◽  
Author(s):  
Arjunan Ganesh ◽  
N Scott Adzick ◽  
Travis Foster ◽  
Giovanni Cucchiaro
Keyword(s):  
Side Effects ◽  
Lung Resection ◽  
Epidural Fentanyl ◽  
Double Blind Study ◽  
Double Blind ◽  
Rescue Dose ◽  
Pain Scores ◽  
Epidural Bupivacaine ◽  
Group B ◽  
To Receive

Background The authors evaluated the efficacy of adding fentanyl to epidural bupivacaine in infants up to 6 months of age after a thoracotomy in a prospective, randomized, double-blind study. The primary outcome was the total amount of rescue doses of intravenous nalbuphine in the first 24 h after surgery. Secondary outcomes included (1) time to first rescue dose of nalbuphine, (2) pain scores, and (3) behavior scores. Methods Thirty-two infants were randomly assigned to receive an epidural infusion containing 0.1% bupivacaine (group B; n = 16) or 0.1% bupivacaine and 2 microg/ml fentanyl (group BF; n = 16). Patients were evaluated up to 24 h after surgery for pain; amount of analgesic rescues and time to first rescue; pain scores; behavior scores (five-item behavior score); and complications, including respiratory depression, oxygen requirement, vomiting, and urinary retention. Results The two groups had similar demographics. Nalbuphine consumption (P = 0.001) and pain scores (P &lt; 0.001) in the first 24 h were significantly decreased in group BF compared with group B. The time to first analgesic rescue was significantly longer in group BF (P = 0.005). The five-item behavior score was significantly better in group BF than in group B (P = 0.01). The incidence of side effects, the time to first successful feeding, and the time to discharge were similar in both groups. Conclusions Addition of 2 microg/ml epidural fentanyl to 0.1% bupivacaine results in improved postthoracotomy analgesia without any increase in side effects, compared with 0.1% bupivacaine, in infants up to 6 months of age.

scholarly journals Intramuscular Ketorolac for Postoperative Analgesia following Laparoscopic Sterilisation

1994 ◽  
Vol 22 (1) ◽  
pp. 22-24 ◽  
Author(s):  
M. H. Shapiro ◽  
B. L. Duffy
Keyword(s):  
Side Effects ◽  
Intramuscular Injection ◽  
Double Blind Study ◽  
Day Case ◽  
Double Blind ◽  
Apparent Lack ◽  
Pain Scores ◽  
Significant Difference ◽  
To Receive ◽  
Intramuscular Ketorolac

The analgesic effect of intramuscular ketorolac was assessed by double blind study in forty women presenting for day-case laparoscopic sterilisation. The patients were randomly allocated to receive either ketorolac 30 mg or saline by intramuscular injection immediately following induction of general anaesthesia. There was no statistically significant difference between the groups in pain scores, opioid requirements or incidence of nausea and vomiting in the postoperative period. In view of the potential side-effects of ketorolac, and the apparent lack of efficacy when used prophylactically, the routine use of the drug in this group of patients cannot be recommended.

Drug therapy and tinnitus: the UK experience

1984 ◽  
Vol 98 (S9) ◽  
pp. 277-280 ◽  
Author(s):  
J. W. P. Hazell ◽  
S. M. Wood
Keyword(s):  
Drug Therapy ◽  
Side Effects ◽  
Active Ingredient ◽  
Placebo Response ◽  
Central Component ◽  
Controlled Trials ◽  
Double Blind Study ◽  
Double Blind ◽  
Low Incidence ◽  
The Uk

SummaryThere have been five recent studies of drug treatment in tinnitus in the UK using Class I anti-arrhythmic preparations. We present a new double-blind study of tocainide hydrochloride in severe, unmaskable tinnitus. No significant response is noted in any of the controlled trials to the active ingredient, and more work is needed on diagnostic criteria to see if those who do respond constitute a separate group. There was a surprisingly low incidence of placebo response and the importance of the side effects produced by the drugs in this group is stressed. The finding that three patients with profound hearing losses have had some continued benefit leads to the cautious conclusion that drug responders may be have a central component to their tinnitus.

Duloxetine augmentation in resistant obsessive compulsive disorder: Surveying a new medication for challenges in treatment of OCD

2017 ◽  
Vol 41 (S1) ◽  
pp. S415-S415
Author(s):  
A. Mowla
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Primary Outcome Measure ◽  
Controlled Clinical Trial ◽  
Double Blind Study ◽  
Obsessive Compulsive ◽  
Double Blind ◽  
Compulsive Disorder ◽  
Significant Difference ◽  
Competing Interest ◽  
To Receive

IntroductionUp to 50% of patients with OCD have failed to respond in SSRI trials, so looking for pharmacological alternatives in treatment of obsessive compulsive disorder (OCD) seems necessary.ObjectivesSurveying duloxetine augmentation in treatment of resistant OCD.AimsStudy the effects of serotonin-norepinephrine enhancers for treatment of OCD.MethodsThis augmentation trial was designed as an 8-week randomized controlled, double blind study. Forty-six patients suffering from OCD who had failed to respond to at least 12 weeks of treatment with a selective serotonin reuptake inhibitor (fluoxetine, citalopram or fluvoxamine) were randomly allocated to receive duloxetine or sertraline plus their current anti OCD treatment. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) was the primary outcome measure.ResultsForty-six patients (24 of 30 in duloxetine group and 22 of 27 in sertraline group) completed the trial. Both groups showed improvement over the 8-week study period (mean Y-BOCS total score at week 8 as compared with baseline: P < 0.001 and P < 0.001) without significant difference (P = 0.861). Those receiving duloxetine plus their initial medications experienced a mean decrease of 33.0% in Y-BOCS score and the patients with sertraline added to their initial medication experienced a mean decrease of 34.5% in Y-BOCS.ConclusionsOur double blind controlled clinical trial showed duloxetine to be as effective as sertraline in reducing obsessive and compulsive symptoms in resistant OCD patients. However, it needs to be noted that our study is preliminary and larger double blind placebo controlled studies are necessary to confirm the results.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Azelastine in the Prophylactic Treatment of Bronchial Asthma: An Italian Multicentre Comparison with Ketotifen

1989 ◽  
Vol 17 (3) ◽  
pp. 218-225 ◽  
Author(s):  
L. Ambrosi ◽  
F. Bariffi ◽  
M. Carino ◽  
E. Catena ◽  
G. Ceccarelli ◽  
...  
Keyword(s):  
Bronchial Asthma ◽  
Double Blind Study ◽  
Double Blind ◽  
Significant Difference ◽  
Effective Prophylaxis ◽  
Daily Dosage Regimen ◽  
Forced Expiratory Flow ◽  
Expiratory Flow ◽  
Low Incidence ◽  
Clinical Measures

The prophylactic effectiveness of the phthalazinone derivative, azelastine was compared with ketotifen. A total of 111 patients, aged 18 – 65 years, from 10 centres was entered into this randomized, double-blind study. All patients had reversible asthma. After 1 week on placebo, patients were allocated to either 8 mg/day azelastine once or twice daily, or to 1 mg ketotifen, twice daily, for a further 12 weeks. Azelastine was more effective in improving respiratory function (forced expiratory flow in 1 s and peak expiratory flow rate) when given in the once daily regimen, whereas clinical measures (number of weekly asthma attacks) were most improved by twice daily dosing. There was no significant difference between the effectiveness of azelastine and that of ketotifen. Treatments were equally well tolerated and a low incidence of side-effects was reported. In conclusion, 8 mg/day azelastine, in either a single or twice daily dosage regimen may be regarded as providing effective prophylaxis against bronchial asthma.

scholarly journals Intravenous chlorpromazine in the acute treatment of episodic tension-type headache: a randomized, placebo controlled, double-blind study

2002 ◽  
Vol 60 (3A) ◽  
pp. 537-541 ◽  
Author(s):  
Marcelo Eduardo Bigal ◽  
Carlos Alberto Bordini ◽  
José Geraldo Speciali
Keyword(s):  
Acute Treatment ◽  
Tension Type Headache ◽  
Blind Study ◽  
Number Needed To Treat ◽  
Double Blind Study ◽  
Emergency Rooms ◽  
Double Blind ◽  
Therapeutic Gain ◽  
Type Headache ◽  
To Receive

Acute headache is a very frequent symptom, responsible for a significant percentage of caseload at primary care units and emergency rooms. Chlorpromazine is easily available in such settings. The aim of this study is to conduct a randomized, placebo-controlled, double-blind study to assess the efficacy of chlorpromazine on the acute treatment of episodic tension-type headache. We randomized 30 patients to receive placebo (10 ml of saline intravenous injections) and 30 patients to receive 0.1 mg/Kg chlorpromazine intravenously. We used 7 parameters of analgesic evaluation. Patients receiving chlorpromazine showed a statistically significant improvement (p < 0.05 and p < 0.01) of pain compared to placebo, far up to 30 minutes after the drug administration. The therapeutic gain was 36.7% in 30 minutes and 56.6 % in 60 minutes. The number needed to treat (NNT, the reciprocal or the therapeutic gain) was 2.7 in 30 minutes and 1.8 in 60 minutes. There were reductions in the recurrence and in the use of rescue medication in the chlorpromazine group. We can conclude that intravenous chlorpromazine is an effective drug to relief the pain in tension-type headache.

Sign in / Sign up

Export Citation Format

Share Document